- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00509938
Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
Safety and Efficacy of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients Part A: Clinical Study Protocol SC12: Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
Study Overview
Status
Intervention / Treatment
Detailed Description
Background:
Human lactoferrin (hLF) is a glycoprotein containing 692 amino acids and found in the saliva, milk, tears, and other body fluids. Peptide representing the first cationic domain, i.e. a peptide comprising the first eleven residues of hLF (further referred to as hLF1-11) was significantly more effective than the full length hLF or the peptide representing the second cationic domain in killing a variety of bacteria in vivo. The mechanism of action comprises a number of independent factors. The classical way to explain the efficacy is the direct killing effect, which typically is observed in vitro at relatively high concentrations. The results of in vitro and in vivo experiments suggest that the mechanism of action is predominantly through the intermediary of cells and/or components of the host as opposed to a direct interaction with the pathogen.
The objective is to develop hLF1-11 as an effective and safe antibacterial and antifungal for the treatment of fungal and bacterial infections that develop during the neutropenia that results from myeloablative therapy to prepare for a haematopoietic stem cell transplant (HSCT) formerly referred to as bone marrow transplant. Rates of infection and related morbidity are high in this population making it an attractive target for testing clinically the proof-of-principle that hLF1-11 can provided effective treatment. Subsequently, hLF1-11 will be developed further as a systemic antifungal agent.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- UMC St. Radboud
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- admitted for an autologous HSCT after myeloablative therapy with high-dose melfalan
- managed with a 4-lumen central venous catheter
- BMI <30
- able and willing to participate
- has provided written informed consent
- there is no medical reason for exclusion
- has adequate renal function (creatinine <110 µmol/L (man); <90 µmol/L (woman))
- has adequate liver function (ASAT <40 U; ALAT <45 U; bilirubin <10µmol/L)
- has no known allergy to lactoferrin
- has no history of hepatitis and is not HIV seropositive
- if a woman, functionally post-menopausal
Exclusion Criteria:
- A history of, or presence of, significant respiratory, cardiovascular, neurological, haematological, endocrine, gastrointestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs (as judged clinically relevant by the investigator).
- Participation in a study with a new chemical entity or new molecular entity 3 months before or participation in a study with a registered drug less than 5 times of the half life of the registered drug before entering the study.
- A clinically relevant history of intolerance or hypersensitivity to the study drug, or its additives and excipients in the intravenous formulation.
- Evidence of having serum hepatitis or carrying the hepatitis B surface antigen or Hepatitis C antibodies or being HIV positive.
- Subjects, who in the opinion of the investigator should not, for reasons of safety, participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
5mg hLF1-11, single dose iv
|
Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability by recording the vital signs, clinical chemistry, local tolerability and adverse events during the study
Time Frame: 28 Days
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
formation of antibodies anti-hLF 1-11 during the study.
Time Frame: 28 Days
|
28 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: J.P. Donnelly, PhD, Radboud University Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMP 02-01
- SC12
- IS 044096
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infections and Mycoses
-
University Hospitals Cleveland Medical CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacterial Infections and MycosesUnited States
-
NovaDigm Therapeutics, Inc.United States Department of Defense; Cetero Research, San AntonioCompletedCandidiasis | Staphylococcal InfectionsUnited States
-
Sir Run Run Shaw HospitalUniversity of BirminghamUnknown
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
Clinical Trials on human lactoferrin peptide 1-11
-
AM-PharmaWithdrawnBacteremia | Staphylococcal InfectionsNetherlands
-
AM-PharmaWithdrawn
-
AM-PharmaWithdrawnFungal Infection | Bacterial InfectionNetherlands
-
Midwest Center for Metabolic and Cardiovascular...HelainaCompletedImmune HealthUnited States
-
Johns Hopkins UniversityVentria BioscienceUnknownClostridium DifficileUnited States
-
AgennixCompletedCarcinoma, Renal CellUnited States
-
Herlev HospitalUniversity of Copenhagen; The Danish Medical Research Council; The Danish Diabetes...Completed
-
Shahid Beheshti University of Medical Sciencespraxisgemeinschaft für zelltherapieUnknownCovid19 | Corona Virus Infection | TreatmentIran, Islamic Republic of
-
University Hospital, Gentofte, CopenhagenDanish Heart FoundationCompletedType 2 Diabetes | Blood Flow | Human Physiology | Glucagon-like Peptide-1 | Blod PressureDenmark
-
National Cancer Institute (NCI)CompletedCervical Cancer | Head and Neck Cancer | Esophageal Cancer | Vulvar Cancer | Anal Cancer | Penile CancerUnited States